Genesis Molecular AI logo

Genesis Molecular AI

Unifying AI and Biotech to accelerate the discovery of new medicines

158 employees · est. 2019 · San Mateo, United States

VS
iktos logo

iktos

Artificial intelligence for new drug design

85 employees · est. 2016 · Paris, France

iktos is the older company (2019 vs 2016).

Side-by-Side Comparison

Genesis Molecular AI iktos
Founded
2019 2016 older
Headquarters
San Mateo, United States Paris, France
Employees
158 85
Industry
AI, Biotechnology, Information Technology AI, Biotechnology, Health Care
Funding Stage
Unknown Series A
Total Funding
$280.13M $18.90M
Funding Rounds
5 7
Services
AI Research and Development, Molecular Design Platforms, Drug Discovery Solutions, AI Model Capabilities Enhancement Generative AI Platform (Makya), AI-Driven Retrosynthesis (Spaya), Automated Drug Development Pipeline, Autonomous Lab Robotics
Target Customers
Pharmaceutical Companies, Biotechnology Firms, Research Institutions, Drug Development Teams Pharmaceutical Companies, Biotech Firms, Academic Institutions, Medicinal and Computational Chemists, Drug Discovery Teams
Taxonomy
Molecular AI, Drug Discovery, Generative AI, Predictive AI, GEMS Platform, Small Molecule Drugs, Structure Prediction, AI-Enabled Discovery, Lead Optimization, Biophysics Simulation, Neural Networks, Computational Chemistry, Undruggable Targets, AI Collaborations, Pharmaceutical Innovation Drug Design, Medicinal Chemistry, Generative AI, Chemoinformatics, Robotics Automation, SaaS Software, Molecular Modeling, Oncology, Retrosynthesis, Protein-Protein Interactions, RNA-Protein Interactions, Synthesis Automation, Pharmaceutical R&D, Lead Optimization
Website
genesistherapeutics.ai iktos.ai
Genesis Molecular AI logo

About Genesis Molecular AI

Genesis Molecular AI, founded in 2019 and headquartered in the United States, is at the forefront of merging AI and Biotechnology to enhance drug discovery processes. With an innovative slogan, “Unifying AI and Biotech to accelerate the discovery of new medicines,” the company is redefining drug des...

iktos logo

About iktos

Iktos, founded in 2016 and headquartered in France, stands out as a leader in the convergence of AI and biotechnology for drug discovery. Its slogan, "Artificial intelligence for new drug design," encapsulates its mission to leverage cutting-edge technologies for medicinal chemistry. The company's...

We will tell you when either one moves

BounceWatch watches Genesis Molecular AI and iktos for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Genesis Molecular AI and iktos — by email.

Frequently Asked Questions

Genesis Molecular AI — Unifying AI and Biotech to accelerate the discovery of new medicines. iktos — Artificial intelligence for new drug design. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Genesis Molecular AI has raised $280.13M while iktos has raised $18.90M.
Genesis Molecular AI and iktos operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Genesis Molecular AI with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Genesis Molecular AI on 18 Sep 2026, and iktos on 20 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy